Stock NVCR NOVOCURE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Real-time Estimate Cboe BZX
Other stock markets
 17:57:00 29/04/2024 BST 		5-day change 1st Jan Change
12.85 USD +1.70% Intraday chart for NovoCure Limited +8.83% -13.76%
04-24 NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer CI
04-10 Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
BU
NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer
CI
NovoCure : Corporate responsibility report
PU
Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating
MT
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research Annual Meeting 2024
AQ
NovoCure Says New Data Show TTFields' Potential Therapeutic Effects in Pancreatic Cancer
MT
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
BU
Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating
MT
Novocure to Report First Quarter 2024 Financial Results
BU
Novocure - METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
AQ
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases
AQ
Zai Lab, Novocure Say TTFields Therapy Delays Intracranial Progression in Non-Small Cell Lung Cancer Brain Metastases Patients
MT
Sector Update: Health Care Stocks Edge Higher Pre-Bell Wednesday
MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data
MT
Sector Update: Health Care
MT
NovoCure Says Trial of Therapy for Brain Metastases From Lung Cancer Met Primary Endpoint; Shares Jump Pre-Bell
MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Board Governor Waller's Speech
MT
Transcript : NovoCure Limited - Special Call
Novocure's lung cancer therapy succeeds in late-stage trial
RE
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NVCR Stock
  4. News NovoCure Limited